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Abstract: Chronic pain arising from various pathological conditions such as osteoarthritis, 
low back or spinal injuries, cancer, and urological chronic pelvic pain syndromes presents 
significant challenges in diagnosis and treatment. Specifically, since the underlying cause of 
these pain syndromes is unknown or heterogeneous, physicians diagnose and treat patients 
based on the symptoms presented. Nerve growth factor (NGF) has been recognized as an 
important mediator of chronic pain in many pathological conditions, and has been shown to be 
upregulated in a subset of individuals suffering from such pain syndromes. These findings have 
led to the development of anti-NGF monoclonal antibodies such as tanezumab as potentially 
effective therapeutics for chronic pain. Although tanezumab has reached Phase II and III clini-
cal trials, the trials of anti-NGF antibodies were halted due to safety concerns. Some of these 
trials of anti-NGF treatment have had statistically significant decreases in pain, while others 
have yielded inconclusive results. These findings are suggestive of, though do not prove, target 
(NGF) neutralization in chronic pain syndromes. A biomarker-driven anti-NGF clinical study 
layout is proposed that incorporates NGF measurements in the relevant samples before and 
after treatment, in addition to collecting the pain scores. This approach might not only confirm 
the mechanism of tanezumab’s action in these chronic pain patients, but should establish NGF 
levels as a predictive biomarker for patients who can benefit from anti-NGF treatment, thereby 
creating a personalized approach to pain treatment.
Keywords: nerve growth factor, chronic pain, anti-NGF antibodies, neurotrophic factor, 
nociceptor neurons
Introduction
Medically unexplained chronic pain arising from various pathological conditions pres-
ents significant challenges in diagnosis and treatment. Such chronic pain conditions 
include osteoarthritis, low back or spinal injuries, cancer, urological chronic pelvic 
pain syndromes, and many others. Operationally, clinicians are often dependent on 
standard diagnostic categories, which might not have captured the full spectrum of 
heterogeneity of these pain symptoms. Heterogeneity of the underlying signals for 
chronic pain has been substantiated by the involvement of inflammatory mediators, 
peripheral neuropathy, post-herpetic reactions, and local production of neurotrophins 
in several of these pathological conditions.1,2 Current therapies for chronic pain include 
nonsteroidal anti-inflammatory drugs, antiseizure agents, and opiates, but the results 
are less than satisfactory in most cases and have often proved toxic with long-term 
use.1,3,4 More recently, nerve growth factor (NGF) has been recognized as an important 
mediator of chronic pain syndromes.3 Therefore, different methods to block the NGF 
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signaling at the receptor level or by antibodies against NGF 
have been tested in preclinical studies as well as in clinical 
trials. Many humanized anti-NGF monoclonal antibodies 
have entered clinical trials as potential pain therapies, and 
tanezumab (an anti-NGF antibody developed by Pfizer, Inc, 
New York, NY) has advanced beyond the proof-of-concept 
studies to Phase III trials in osteoarthritis. The role of NGF 
in pain transduction, antibodies that block NGF signaling, 
outcomes of previous proof-of-concept studies on anti-NGF 
antibodies, and potential benefit of personalized treatment 
based on biomarker assays are the topics of this review.
Nerve growth factor and its 
receptors in pain sensation
Unexpectedly discovered in tumor cells and salivary 
glands, NGF is the first neurotrophic factor to be identified, 
purified, and biochemically characterized.5–7 NGF is a 
13 kDa polypeptide secreted as a dimer from target cells 
of sympathetic and sensory neurons, and is involved in 
the growth, signaling, and survival of neurons.8,9 In the 
developing nervous system, the primary role of NGF is in 
neuronal survival, but this role shifts in adults to a more 
protective role at the organismal level by mediating pain from 
noxious stimuli.1,3,10 Afferent nociceptor fibers that conduct 
pain signals to the central nervous system include the small-
diameter, unmyelinated, slow-conducting C fibers and the 
small-to-medium diameter, lightly myelinated, relatively 
rapid-conducting Aδ fibers.2 The Aδ fibers mediate acute/
sharp pain, whereas the C fibers mediate dull/diffuse pain. 
These nociceptor fibers that innervate the different parts of the 
body and head conduct pain signals to the dorsal root ganglia 
of the spinal cord or the trigeminal ganglia, respectively.2
The signaling of NGF in these nociceptor neurons is 
mediated through two different receptors, the low-affinity 
75 kDa neurotrophin receptor (p75NTR), which belongs 
to the TNF receptor family, as well as the high-affinity 
tropomyosin-related kinase A (TrkA), a receptor tyrosine 
kinase.9,11 P75NTR binds neurotrophins such as BDNF, NT3, 
and NT4, whereas TrkA binds NGF more selectively than 
the other neurotrophins.11 Signaling through TrkA mediates 
neurotrophic effects during development, and also mediates 
the nociceptive functions of the sensory neurons in adult 
life.10,12 p75NTR signaling in the absence or low expression 
of TrkA mediates apoptosis, whereas TrkA signaling blocks 
this apoptotic effect and enhances neuronal survival.13,14 
The interesting aspect of NGF/TrkA signaling in the 
nociceptor neurons is that in addition to its role in neuronal 
survival by inhibition of apoptosis, the same signaling 
pathway leads to the generation of action potentials for 
the neuronal signaling of pain sensation.15,16 Functional 
nociceptors selectively express the NGF receptor TrkA, 
the neuropeptides’   substance P and calcitonin gene-related 
peptide (CGRP), as well as the Transient Receptor Potential 
Vanilloid 1 (TRPV1), which are important in the nociceptive 
function.17,18 Immunohistochemical studies on rat dorsal root 
ganglia have shown that a great majority (.90%) of the TrkA 
expressing neurons were CGRP-expressing small-diameter 
sensory neurons of the peptidergic C type sensory fibers.19 
Extensive studies using dorsal root ganglia neurons and 
gene-transferred non-neuronal cells have demonstrated that 
TRPV1 acts as a non-selective cation channel and plays an 
important role in the conduction of nociceptive signals.15,16 
NGF signaling through TrkA activates the cellular protein 
kinases of the phosphatidylinositol 3-kinase (PI3K) and Ras 
signaling pathway, which leads to the phosphorylation and 
activation of TRPV1 for increased channel activity. This 
activation might involve the participation of other kinases, 
particularly protein kinase C (PKC) downstream of PI3K 
(Figure 1).10,15,18
Tanezumab does not appreciably cross the blood–brain 
barrier, as is evident from the preclinical studies of anti-NGF 
antibodies.8,20 The analgesic effect of anti-NGF treatment is 
believed to be primarily in the blockade of signaling in the 
CGRP/TrkA-positive peripheral nociceptive fibers. However, 
some indirect effect on the central sensitization has also 
been reported. This is evidenced by the inhibition of c-Fos 
expression in the deep dorsal horn of the spinal cord in the 
anti-NGF-treated rat model of cancer-induced pain.21
Several positive feedbacks exist in the NGF signaling 
loops that potentially enhance the sensation of noxious 
stimuli. First of all, NGF enhances the expression of its 
own receptor TrkA, as experimentally demonstrated in basal 
forebrain neurons from fetal rats.22 Moreover, NGF has 
been shown to enhance the expression of substance P and 
CGRP in the neurons of C fibers, thus sensitizing neurons 
to   hyperalgesia. The release of these nociceptive peptides 
from the neurons in turn stimulate increased production 
of NGF by the target cells of the nociceptive neurons.22,23 
Moreover, TRPV1 phosphorylation resulting from NGF 
signaling through TrkA leads to increased translocation 
of TRPV1 channel proteins to the cell surface membrane. 
These positive feedback loops in the NGF signaling amplify 
the TRPV1 channel activity leading to NGF-induced 
hyperalgesia.
The role of NGF in mediating pain in many different 
pathological conditions now has been well established in 
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experimental and clinical contexts. For example, NGF 
levels were increased in skin tissues artificially inflamed 
by treatment with carrageenan, and NGF signaling in this 
model contributed to the pain sensitization by the afferent 
nociceptive neurons.24 This is evidenced by the observation 
that neutralization of NGF by the soluble NGF receptor 
fusion molecule TrkA-IgG reversed the inflammatory pain 
sensitization.24,25 Similarly, another TrkA soluble receptor, 
TrkAd5, has been shown to be effective against pain in 
experimentally induced osteoarthritis in rats, demonstrat-
ing the role of NGF signaling in mediating osteoarthritic 
pain.26 Genetic evidence for the role of NGF in pain signals 
comes from a single substitution mutation, R100W, in the 
NGF gene that resulted in defective processing of the pre-
cursor protein and the accompanying changes in the bind-
ing affinity to the receptors, leading to severe reduction of 
pain perception.27 However, kinase domain mutations in the 
TrkA gene itself that affect NGF signaling resulted in more 
extensive abnormalities including a human disorder named 
  congenital insensitivity to pain with anhidrosis (CIPA), 
behavioral defects, and mental retardation.28
There are several clinical situations in which elevated 
levels of NGF have been implicated in human chronic 
pain syndromes, such as interstitial cystitis/painful bladder 
syndrome (IC/PBS), chronic prostatitis/chronic pelvic 
pain syndrome (CP/CPPS), osteoarthritis (OA), diabetic 
peripheral neuropathy, and psoriasis, and which can serve 
as biomarkers for the underlying pain mechanism.3,29–32 For 
example, NGF overexpression in the bladder contributes to 
the regulation of afferent neural plasticity and reorganization 
of the micturition pathways in overactive bladder syndrome 
(OAB) and interstitial cystitis/painful bladder syndrome 
(IC/PBS).30 In the clinical settings, elevated levels of 
urinary NGF have been reported to be reliable biomarkers 
for overactive bladder.33 Similarly, elevated urinary NGF 
levels were observed in patients with IC/PBS compared 
to normal controls in a clinical study, and a decrease 
in urinary NGF was associated with pain reduction in 
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Figure 1 NGF signaling pathways in mediating neurotrophic and nociceptor effects.
Notes: NGF signals through the high-affinity TrkA and low p75NTR receptors. TrkA activates both PI3 kinase (PI3K) and Ras pathways, which lead to cell survival and 
neurite outgrowth. Signaling through p75NTR leads to apoptosis, which is blocked by the TrkA-activated PI3K pathway. PI3K activation also leads to activation of the non-
selective cation channel TRPV1 by phosphorylation, thereby generating action potential for nociceptive functions. Moreover, TRPV1 phosphorylation results in increased 
translocation of TRPV1 to the plasma membrane to enhance channel activity.  Antibody-mediated NGF blockade results in the abolition of both neurotrophic and 
nociceptor functions.
Abbreviation: NGF, nerve growth factor.
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response to different treatments such as hydrodistension, 
oral pentosan polysulphate, hyaluronic acid instillation, or 
BoNT-A injections.29 In a small clinical study involving 20 
CP/CPPS patients and four control subjects, the expressed 
prostatic secretion (EPS) contained significantly higher 
levels of NGF than the control group. There was clear 
correlation between the NGF levels and pain severity in 
the patients with CP/CPPS.32 The patients who responded 
to treatment showed a significant reduction in the NGF 
levels from the baseline. Therefore, NGF levels in the EPS 
can serve as a biomarker for the severity of pain and as a 
measure of treatment response.
Chronic pain associated with advanced malignancies has 
also been shown to be related to NGF signaling. Prostate and 
breast cancers, which frequently result in bone metastases, 
are characterized by severe bone pain. In experimental tumor 
models in rats, NGF produced by the tumor cells and/or 
tumor-associated stromal cells has been implicated in the 
extensive sprouting of sensory neural fibers from the bone 
tissue and the resulting hyperalgesia.34,35
In streptozotocin-induced diabetes in rats, elevated NGF 
levels in the skin have been observed along with an increase 
in the proportion of TrkA-expressing, CGRP-positive neu-
rons, indicating a role for NGF in painful diabetic neuropathy, 
although the enhanced NGF production might be a natural 
response to protect the sensory neurons affected by diabetic 
conditions.36
Therapeutic potential of NGF 
modulation
The aforementioned studies establish the role of NGF as 
an important modulator of pain sensation in many differ-
ent pathological conditions and have led to investigations 
on the therapeutic strategies for blocking NGF signaling. 
Studies in a mouse model of bone metastasis of prostate 
cancer demonstrated that systemic administration of anti-
NGF monoclonal antibodies prevented tumor-associated 
pain behavior and neural sprouting in the vicinity of the 
tumor, irrespective of the time of starting the therapy rela-
tive to the establishment of tumor.37 Most of the sensory 
nerve fibers that innervate bone are the small-diameter 
types that express TrkA and CGRP peptide, and there-
fore blocking these fibers is unlikely to be compensated 
by alternative nociceptive fibers.21 In another study of 
autoimmune arthritis in rats, anti-NGF antibodies almost 
completely eliminated the joint pain, but the underlying 
inflammatory pathology was not changed.38 Therefore, this 
highly effective blocking of the sensory signals of joint 
pain sometimes has the negative effect of encouraging 
the overuse of an affected bone or joint, as in the case of 
osteoarthritis discussed later.
Tanezumab: an NGF-targeted 
approach to treating chronic pain
Tanezumab is a humanized IgG2 monoclonal antibody 
against NGF developed by Pfizer Inc, based on evidence 
linking NGF to chronic pain.39,40 Tanezumab was designed 
to block the NGF-receptor interaction, thus preventing the 
signaling through the sensory and sympathetic neurons 
for the   perception of pain. Other antibodies against 
NGF such as REGN 475 (Regeneron, Tarrytown, NY), 
  fulranumab (Johnson & Johnson, New Brunswick, NJ), 
PG110 (Abbott Laboratories, Abbott Park, IL), and MEDI 
578 (AstraZeneca, London, UK) are also in early phases of 
clinical development.41–43 This review will mainly focus on 
tanezumab, which is at an advanced stage of development 
in multiple chronic pain conditions, although the discussion 
will be generally applicable to other NGF antibodies also. 
Tanezumab shows tight binding to NGF and the complex 
has a half-life of .100 hours.39 Pharmacokinetic and 
toxicological studies in cynomolgus monkeys by weekly 
intravenous administration for 26 weeks followed by 8 weeks 
recovery period did not show adverse events (AEs) or any 
histological abnormalities in brain, spinal cord, nerves, or 
ganglia.44 To evaluate its clinical efficacy in the treatment of 
chronic pain syndromes, tanezumab was studied in patients 
with osteoarthritis, chronic lower back pain, urological 
chronic pelvic pain syndromes, painful diabetic neuropathy, 
and cancer pain. Some of the representative studies are 
described here.
In a Phase II proof-of-concept study, 450 patients with 
moderate-to-severe osteoarthritis of the knee were randomly 
assigned to receive two intravenous (iv) administrations of 
tanezumab at 10, 25, 50, 100, and 200 µg/kg or placebo 
8 weeks apart.45 Tanezumab treatment resulted in substantial 
improvement in the primary efficacy measures of knee pain 
during walking as well as in global assessment of response 
to therapy. There was a 45%–62% reduction in knee pain 
from the baseline in the different dose groups averaged over 
a 16-week period, compared to 22% reduction in the placebo 
group. The most common adverse events were mild-to-
moderate headache, respiratory infections, and changes in 
skin sensation (paresthesia).
A similar study was also conducted in Japanese patients 
having moderate-to-severe OA in the knee, with improve-
ments in knee pain following a single iv administration of 
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different doses of tanezumab up to 200 µg/kg versus placebo, 
accompanied by mild-to-moderate AEs of peripheral sensa-
tion that were transient in nature.46 Tanezumab was also 
evaluated for long-term effects in another Phase II repeat 
dose study by administration of 50 µg/kg every 8 weeks for 
a maximum of eight doses in OA patients.47 While significant 
improvement in overall knee pain was observed, treatment-
related AEs were mild and of low incidence (7.5%), mostly 
hypoesthesia and paresthesia, most of which resolved before 
study completion.
Tanezumab was tested for its efficacy for chronic low 
back pain (LBP) in a Phase II trial of 220 chronic LBP 
patients who were on analgesic medication for at least 
3 months and having an average LBP intensity (aLBPI) score 
of $4 using an 11-point numeric rating scale (NRS).48 The 
patients received a single iv dose of 200 µg/kg tanezumab 
(the maximal dose tested in the OA studies), naproxen (a 
common nonsteroidal anti-inflammatory drug) at 500 mg 
twice a day for 12 weeks, or placebo in a 2:2:1 ratio and 
observed over a 12-week period. At week 6, the number 
of patients showing $30% and $50% reduction in aLBPI 
score was much higher in the tanezumab group compared 
to the naproxen and placebo groups. Tanezumab was supe-
rior to both naproxen and placebo at weeks 4 to 12 with a 
higher proportion of patients showing $30% reduction in 
aLBPI score.
In a similar Phase II study in patients with interstitial 
cystitis, 34 patients received a single iv dose of tanezumab 
at 200 µg/kg and 30 patients received placebo.8 At 6 weeks, 
the tanezumab cohort showed significant reduction in the 
average pain score on an 11-point NRS versus placebo as 
the primary end point. Tanezumab safety and efficacy were 
also evaluated in a Phase II trial of patients with moderate-
to-severe CP/CPPS (NIH CPSI of $15) with an average 
daily pain score of $4 on a 10-point NRS (ClinicalTrials.
gov identifier: NCT00826514).49,50 Sixty-two patients were 
randomized to receive either a single iv administration of 
20 mg tanezumab or placebo and followed up for 16 weeks. 
The primary efficacy endpoint consisted of changes in the 
average daily NRS pain score from the baseline to week 6. 
However, in this case, the patients showed only a marginal 
improvement in the average daily pain score that was not 
statistically significant. This result was different from the 
outcome of other studies of tanezumab in osteoarthritis and 
low back pain where the tanezumab cohort showed substan-
tial pain reduction over the placebo or active comparator 
cohorts. One explanation for this observation could be that 
CP/CPPS is very heterogeneous in the etiology, and selection 
of patients based on appropriate criteria might improve the 
response to tanezumab.51
Following successful proof-of-concept studies of tan-
ezumab, several Phase II and III trials in patients with 
osteoarthritis of the knee or hip have been underway.42 
However, a significant number of patients had worsening 
of osteoarthritis, probably due to overuse of the joints after 
improvements in pain due to tanezumab therapy.45,51 This 
led to a clinical hold by the FDA on all trials of osteoarthri-
tis, and later the clinical hold was extended to trials on all 
indications except cancer pain (ClinicalTrials.gov Identifier: 
NCT01146561).45,52,53 However, it is possible that tanezumab 
still holds promise as a highly efficacious therapy for chronic 
pain arising from different pathological conditions, with only 
mild-to-moderate drug-related AEs, which are mainly related 
to peripheral sensation. In some pathological conditions, such 
as osteoarthritis or diabetic peripheral neuropathy, closer 
monitoring of the disease condition is essential, because 
tanezumab mainly reduces the chronic pain associated with 
the condition, but the underlying cause of the disease might 
persist in many cases.
Lessons learned from previous 
tanezumab trials
Adverse events comparable to those seen in the OA trials are 
yet to be observed in trials involving other pain syndromes, 
such as urological pelvic pain syndromes, but many studies 
have been terminated or halted to further assess the safety 
issues.45,52 Recent clinical studies investigating the efficacy 
of tanezumab as a treatment for IC/PBS, CP/CPPS, or related 
pain conditions have shown that tanezumab might provide 
some symptom improvement compared with placebo.8,30,50 
However, the lack of conclusive evidence may be attributed 
to individual variation in NGF levels in the affected tissues 
or organs of patients who present similar symptoms (pain, 
urgency, frequency), which might present a unique challenge 
in the design of clinical trials.
In such cases, the true effect of tanezumab may not 
be apparent due to inherent baseline variations in NGF 
levels, ie, some patients that experience chronic pain may 
intrinsically have low NGF levels and therefore benefit 
less from anti-NGF treatment, as may be the case if the 
pain is due to central sensitization or due to other inflam-
matory conditions. Therefore, a reasonable hypothesis 
is that tanezumab might show significant improvements 
in chronic pain in patients who have a certain threshold 
level of NGF in the secretions or fluids collected from the 
affected organs.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
283
NGF – the TrkA to successful pain treatmentJournal of Pain Research 2012:5
A biomarker-guided approach  
to tanezumab treatment
As a follow-up on the lack of conclusive evidence of tan-
ezumab’s effects in some of the chronic pain syndromes 
studied in non-selected populations (and the adverse effects 
revealed in the OA study), future clinical studies might 
  benefit from enriching the enrollment of potential responders 
in the study based on the baseline NGF levels as a biomarker. 
Clinical trials in a nonselected population might dilute the 
true effect of the therapy with the negative results from the 
non-responders and fail to demonstrate the robustness of 
clinical benefits in the target population. The key to designing 
future trials is to unravel the etiology (ie, NGF expression) 
behind the studied pain syndromes and to examine the 
interplay with tanezumab, rather than nonselectively treating 
for the symptom of pain.
In order to establish a mechanistic relation between 
tanezumab therapy and pain reduction, a clinical study that 
would incorporate the assessment of NGF as a biomarker is 
recommended. The study should measure pre-treatment NGF 
levels as a predictive biomarker for identification of potential 
responders, and measure posttreatment NGF levels as a phar-
macodynamic biomarker for evaluating early signs of treat-
ment efficacy. The correlation between the analgesic efficacy 
of the treatment and reduction in the NGF levels posttreatment 
can then be evaluated from pre- and posttreatment standard-
ized pain scores and NGF measurements. A statistically signif-
icant correlation between these para  meters would be a direct 
proof of mechanism of the action of the tanezumab therapy 
in chronic pain disorders, establishing baseline NGF levels as 
a predictive biomarker for various chronic pain syndromes 
for response to tanezumab treatment. A lack of correlation 
between NGF levels and the analgesic effect would indicate 
that tanezumab action may also be indirectly functioning 
through other mediators or pathways.
A two-phase optimization  
of tanezumab study: UCPPS  
as a paradigm
An outline for an optimal clinical investigation of tanezumab 
is recommended here by using urologic chronic pelvic pain 
syndrome (UCPPS) as a paradigm. UCPPS includes both 
CP/CPPS and IC/PBS and should be studied separately to 
have well-defined study populations. A proof-of-concept 
study in patients with CP/CPPS is conducted for evaluating 
the safety, tolerability, and efficacy assessments of tanezumab 
at two potentially optimal doses based on the results from the 
previous trials (for example, two tanezumab cohorts of 100 and 
200 µg/kg administered twice, 8 weeks apart, and a placebo 
group) (Figure 2A). This phase will also have the secondary 
objective of assessing the direct involvement of NGF as a target 
of the therapy by measuring the NGF levels at pre- and posttreat-
ment time points in the appropriate samples collected (eg, EPS 
and urine in the case of CP/CPPS). If the pain reduction observed 
in response to treatment depends on baseline NGF levels that 
are higher than asymptomatic subjects, the subsequent pivotal 
High NGF level Low NGF levels
Measure NGF
levels and pain 
scores
Washout of prior 
medication 
Enroll patients
Stratify
patients
Tanezumab
(optimal dosage) 
Measure NGF
levels and pain 
scores
Tanezumab
High dose
Tanezumab
Low dose Placebo
Measure NGF
levels and pain
scores
Measure NGF
levels and pain 
scores
Washout of prior
medication 
Enroll patients
Proof-of-concept study Pivotal study  B A
Figure 2 Proposed study schema to assess NGF-dependence of tanezumab efficacy. (A) Proof-of-concept study in which NGF is measured in EPS and urine before and after 
treatment with placebo or tanezumab at two different doses. (B) Pivotal study in which NGF levels are measured at pre- and posttreatment time points to establish NGF 
levels as a predictive biomarker for anti-NGF therapy.
Abbreviations: EPS, expressed prostatic secretion; NGF, nerve growth factor.
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studies should include the baseline NGF level (high/low) as a 
patient stratification criterion (Figure 2B). The low NGF group 
would serve as a control for qualifying the elevated baseline NGF 
as a predictive biomarker for response to tanezumab in the pivotal 
studies. If the pain reduction is accompanied by corresponding 
reductions in the NGF levels in the posttreatment samples at the 
evaluated time points, the posttreatment reduction in the NGF 
levels might serve as early signs of efficacy in the pivotal trial 
even before the perceived pain reduction.
In the case of UCPPS, an acceptable approach to collecting 
the baseline statistics would be to use the DABBEC pheno-
typing system, which addresses the underlying pathophysio-
logical mechanism of UCPPS rather than symptoms alone.54,55 
In the case of CP/CPPS, prostate fluid and urine, collected 
via the relatively noninvasive Meares–Stamey four-glass test, 
can be assayed for NGF by ELISA.32,56,57 In patients having 
IC/PBS and overactive bladder syndrome, urinary NGF can 
be measured pre- and posttreatment.29,33 Synovial fluid and 
serum can serve as the test sample for osteoarthritis studies 
and diabetic neuropathy, respectively.31
Discussion
Many chronic pain syndromes, including UCPPS, are of het-
erogeneous etiology, and careful attention should be paid to the 
underlying mechanism for effective treatment with appropriate 
therapeutic agents. NGF plays an important role in mediat-
ing chronic pain in several pathologic conditions but other 
inflammatory mediators may also contribute to pain sensation. 
Previous clinical trials for evaluating the anti-NGF antibodies, 
particularly tanezumab, as an effective therapy for osteoarthritis 
and other chronic pain syndromes, have established that the 
therapy is effective in reducing the pain in most cases. For 
targeted therapies of pain such as anti-NGF antibodies, best 
responses are expected if the study population is enriched based 
on the NGF levels in the affected tissues. A general recommen-
dation for a two-phase clinical study for anti-NGF antibodies 
such as tanezumab in UCPPS is presented. This general pro-
cedure is applicable to the study of anti-NGF on other chronic 
pain disorders where the etiology for pain is heterogeneous 
by modifying the sample collection for NGF measurement. 
UCPPS serves as a paradigm in this example because of the 
relatively noninvasive and simple techniques used in obtaining 
prostatic fluid and urine for assaying NGF levels. The advantage 
of proving a mechanistic function of tanezumab’s effect is to 
use NGF as a predictive biomarker for tanezumab treatment, 
allowing for personalized medical care.
The information that is gained from these studies aug-
ments existing knowledge regarding the etiology of the pain 
syndrome and isolates those arising from NGF signaling. 
This might allow physicians to optimize treatment efficacy 
by properly selecting patients based on factors such as 
pretreatment NGF levels and standard pain scores. A poten-
tial exploratory addition to the study may be to measure the 
effect of other proinflammatory factors in causing UCPPS 
by performing multiplex immunoassays on the prostatic fluid 
and urine samples. There could be a possibility that only a 
fraction of the population with a chronic pain disorder may 
be affected by abnormal NGF levels, or that NGF levels could 
be just one of the factors in chronic pain. This exploratory 
study of other proinflammatory factors may further elucidate 
the complex mechanisms behind chronic pain syndromes.
Disclosure
The authors report no conflicts of interest in this work.
References
  1.  Hefti FF, Rosenthal A, Walicke PA, et al. Novel class of pain drugs based 
on antagonism of NGF. Trends Pharmacol Sci. 2006;27(2):85–91.
  2.  Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature. 
Sep 2001;413(6852):203–210.
  3.  Watson JJ, Allen SJ, Dawbarn D. Targeting nerve growth factor in pain: 
what is the therapeutic potential? Bio Drugs. 2008;22(6):349–359.
  4.  Woodcock J. A difficult balance – pain management, drug safety, and 
the FDA. N Engl J Med. 2009;361(22):2105–2107.
  5.  Cohen S. Origins of growth factors: NGF and EGF. Ann N Y Acad Sci. 
2004;1038:98–102.
  6.  Tuszynski MH. Nerve growth factor gene delivery: animal models to 
clinical trials. Dev Neurobiol. 2007;67(9):1204–1215.
  7.  Varon S, Conner JM. Nerve growth factor in CNS repair. J Neurotrauma. 
1994;11(5):473–486.
  8.  Evans RJ, Moldwin RM, Cossons N, Darekar A, Mills IW, Scholfield D. 
Proof of concept trial of tanezumab for the treatment of symptoms 
associated with interstitial cystitis. J Urol. 2011;185(5):1716–1721.
  9.  Fiore M, Chaldakov GN, Aloe L. Nerve growth factor as a signaling 
molecule for nerve cells and also for the neuroendocrine-immune 
systems. Rev Neurosci. 2009;20(2):133–145.
  10.  Zhu W, Galoyan SM, Petruska JC, Oxford GS, Mendell LM. A devel-
opmental switch in acute sensitization of small dorsal root ganglion 
(DRG) neurons to capsaicin or noxious heating by NGF. J Neurophysiol. 
2004;92(5):3148–3152.
  11.  Huang EJ, Reichardt LF. Trk receptors: roles in neuronal signal 
transduction. Annu Rev Biochem. 2003;72:609–642.
  12.  Holtzman DM, Kilbridge J, Li Y, et al. TrkA expression in the CNS: 
evidence for the existence of several novel NGF-responsive CNS 
neurons. J Neurosci. 1995;15(2):1567–1576.
  13.  Barrett GL. The p75 neurotrophin receptor and neuronal apoptosis. 
Prog Neurobiol. 2000;61(2):205–229.
  14.  Lad SP, Peterson DA, Bradshaw RA, Neet KE. Individual and combined 
effects of TrkA and p75NTR nerve growth factor receptors. A role for the 
high affinity receptor site. J Biol Chem. 2003;278(27):24808–24817.
  15.  Zhang X, Huang J, McNaughton PA. NGF rapidly increases membrane 
expression of TRPV1 heat-gated ion channels. EMBO J. 2005;24(24): 
4211–4223.
  16.  Zhu W, Oxford GS. Phosphoinositide-3-kinase and mitogen activated 
protein kinase signaling pathways mediate acute NGF sensitization of 
TRPV1. Mol Cell Neurosci. Apr 2007;34(4):689–700.
  17.  McMahon SB. NGF as a mediator of inflammatory pain. Philosophical 
Transactions: Biological Sciences. 1996;351(1338):431–440.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
285
NGF – the TrkA to successful pain treatmentJournal of Pain Research 2012:5
  18.  Bonnington JK, McNaughton PA. Signalling pathways involved in the 
sensitisation of mouse nociceptive neurones by nerve growth factor. 
J Physiol. 2003;551(Pt 2):433–446.
  19.  Averill S, McMahon SB, Clary DO, Reichardt LF, Priestley JV. 
Immunocytochemical localization of trkA receptors in chemically 
identified subgroups of adult rat sensory neurons. Eur J Neurosci. 
1995;7(7):1484–1494.
  20.  Jimenez-Andrade JM, Martin CD, Koewler NJ, et al. Nerve growth 
factor sequestering therapy attenuates non-malignant skeletal pain 
following fracture. Pain. 2007;133(1–3):183–196.
  21.  Sevcik MA, Ghilardi JR, Peters CM, et al. Anti-NGF therapy profoundly 
reduces bone cancer pain and the accompanying increase in markers of 
peripheral and central sensitization. Pain. 2005;115(1–2):128–141.
  22.  Kojima M, Ikeuchi T, Hatanaka H. Role of nerve growth factor in the 
expression of trkA mRNA in cultured embryonic rat basal forebrain 
cholinergic neurons. J Neurosci Res. 1995;42(6):775–783.
  23.  Sofroniew MV, Howe CL, Mobley WC. Nerve growth factor sig-
naling, neuroprotection, and neural repair. Annu Rev Neurosci. 
2001;24:1217–1281.
  24.  Koltzenburg M, Bennett DL, Shelton DL, McMahon SB. Neutralization 
of endogenous NGF prevents the sensitization of nociceptors supplying 
inflamed skin. Eur J Neurosci. 1999;11(5):1698–1704.
  25.  McMahon SB, Bennett DL, Priestley JV , Shelton DL. The biological 
effects of endogenous nerve growth factor on adult sensory neurons 
revealed by a trkA-IgG fusion molecule. Nat Med. 1995;1(8):774–780.
  26.  McNamee KE, Burleigh A, Gompels LL, et al. Treatment of murine 
osteoarthritis with TrkAd5 reveals a pivotal role for nerve growth factor 
in non-inflammatory joint pain. Pain. 2010;149(2):386–392.
  27.  Capsoni S, Covaceuszach S, Marinelli S, et al. Taking pain out of NGF:   
a “painless” NGF mutant, linked to hereditary sensory autonomic neuropathy   
type V , with full neurotrophic activity. PLoS One. 2011;6(2):e17321.
  28.  Indo Y, Tsuruta M, Hayashida Y, et al. Mutations in the TRKA/NGF 
receptor gene in patients with congenital insensitivity to pain with 
anhidrosis. Nat Genet. 1996;13(4):485–488.
  29.  Liu HT, Tyagi P, Chancellor MB, Kuo HC. Urinary nerve growth 
factor level is increased in patients with interstitial cystitis/bladder 
pain syndrome and decreased in responders to treatment. BJU Int. 
2009;104(10):1476–1481.
  30.  Ochodnický P, Cruz CD, Yoshimura N, Michel MC. Nerve growth factor 
in bladder dysfunction: contributing factor, biomarker, and therapeutic 
target. Neurourol Urodyn. 2011;30(7):1227–1241.
  31.  Raychaudhuri SK, Raychaudhuri SP. NGF and its receptor system:   
a new dimension in the pathogenesis of psoriasis and psoriatic arthritis. 
Ann N Y Acad Sci. 2009;1173:470–477.
  32.  Watanabe T, Inoue M, Sasaki K, et al. Nerve growth factor level in 
the prostatic fluid of patients with chronic prostatitis/chronic pelvic 
pain syndrome is correlated with symptom severity and response to 
treatment. BJU Int. 2011;108(2):248–251.
  33.  Kuo HC, Liu HT, Chancellor MB. Urinary nerve growth factor is a better 
biomarker than detrusor wall thickness for the assessment of overactive 
bladder with incontinence. Neurourol Urodyn. 2010;29(3):482–487.
  34.  Bloom AP, Jimenez-Andrade JM, Taylor RN, et al. Breast cancer-
induced bone remodeling, skeletal pain, and sprouting of sensory nerve 
fibers. J Pain. 2011;12(6):698–711.
  35.  Jimenez-Andrade JM, Bloom AP, Stake JI, et al. Pathological   sprouting 
of adult nociceptors in chronic prostate cancer-induced bone pain.   
J Neurosci. 2010;30(44):14649–14656.
  36.  Evans L, Andrew D, Robinson P, Boissonade F, Loescher A. Increased 
cutaneous NGF and CGRP-labelled trkA-positive intra-epidermal nerve 
fibres in rat diabetic skin. Neurosci Lett. 2012;506(1):59–63.
  37.  Jimenez-Andrade JM, Ghilardi JR, Castañeda-Corral G, Kuskowski MA,   
Mantyh PW. Preventive or late administration of anti-NGF therapy 
attenuates tumor-induced nerve sprouting, neuroma formation, and 
cancer pain. Pain. 2011;152(11):2564–2574.
  38.  Shelton DL, Zeller J, Ho WH, Pons J, Rosenthal A. Nerve growth fac-
tor mediates hyperalgesia and cachexia in auto-immune arthritis. Pain. 
2005;116(1–2):8–16.
  39.  Abdiche Y, Malashock DS, Pons J. Probing the binding mechanism 
and affinity of tanezumab, a recombinant humanized anti-NGF mono-
clonal antibody, using a repertoire of biosensors. Protein Science. 
2008;17(8):1326–1335.
  40.  Mantyh P, Tive L, Shelton D. Tanezumab, a humanized anti-nerve 
growth factor antibody for the treatment of pain. The Journal of Pain: 
Official Journal of the American Pain Society. 2009;10(4):S44.
  41.  Cattaneo A. Tanezumab, a recombinant humanized mAb against nerve 
growth factor for the treatment of acute and chronic pain. Curr Opin 
Mol Ther. 2010;12(1):94–106.
  42.  Ekman E, Gimbel J, Bello A, et al. Efficacy and safety of intrave-
nous tanezumab in osteoarthritis hip and knee pain: comparison to 
placebo and naproxen in two phase III studies (NCT00830063 and 
NCT00863304). The Journal of Pain: Official Journal of the American 
Pain Society. 2011;12(4):P55.
  43.  Haddley K. Tanezumab. Anti-NGF monoclonal antibody, Treat-
ment of pain, Treatment of osteoarthritis. Drugs of the Future. 
2010;35(5):373–378.
  44.  Zorbas M, Hurst S, Shelton D, Evans M, Finco D, Butt M. A multiple-
dose toxicity study of tanezumab in cynomolgus monkeys. Regul 
Toxicol Pharmacol. 2011;59(2):334–342.
  45.  Lane NE, Schnitzer TJ, Birbara CA, et al. Tanezumab for the 
treatment of pain from osteoarthritis of the knee. N Engl J Med. 
2010;363(16):1521–1531.
  46.  Nagashima H, Suzuki M, Araki S, Yamabe T, Muto C. Preliminary 
assessment of the safety and efficacy of tanezumab in Japanese 
patients with moderate to severe osteoarthritis of the knee: a ran-
domized, double-blind, dose-escalation, placebo-controlled study. 
Osteoarthritis and Cartilage/OARS, Osteoarthritis Research Society. 
2011;19(12):1405–1412.
  47.  Schnitzer TJ, Lane NE, Birbara C, Smith MD, Simpson SL, Brown MT. 
Long-term open-label study of tanezumab for moderate to severe osteoar-
thritic knee pain. Osteoarthritis Cartilage. 2011;19(6):639–646.
  48.  Katz N, Borenstein DG, Birbara C, et al. Efficacy and safety of tan-
ezumab in the treatment of chronic low back pain. Pain. 2011;152(10): 
2248–2258.
49. Pfizer. An efficacy and safety study of tanezumab for the treatment of 
pain associated with chronic abacterial prostatitis. In: ClinicalTrials.
gov [website on the Internet]. Bethesda, MD: US National Library of 
Medicine; 2009 [updated March 14, 2011]. Available from: http://clini-
caltrials.gov/ct2/show/study/NCT00826514?term=NCT00826514&ran
k=1. NLM identifier: NCT00826514. Accessed April 15, 2012.
  50.  Nickel JC, Atkinson G, Krieger J, et al. Tanezumab therapy for chronic 
prostatitis/chronic pelvic pain syndrome (cp/cpps): preliminary assess-
ment of efficacy and safety in a randomized controlled trial. The Journal 
of Urology. 2011;185(4):e573–e574.
  51.  Strauss AC, Dimitrakov JD. New treatments for chronic prostatitis/
chronic pelvic pain syndrome. Nat Rev Urol. 2010;7(3):127–135.
  52.  Wood JN. Nerve growth factor and pain. N Engl J Med. Oct 2010; 
363(16):1572–1573.
  53.  Pfizer. Safety and efficacy of tanezumab in patients with chronic 
pancreatitis. In: ClinicalTrials.gov [website on the Internet]. Bethesda, 
MD: US National Library of Medicine; 2010 [updated April 13, 2011]. 
Available from: http://clinicaltrials.gov/ct2/show/NCT01146561?term
=NCT01146561&rank=1. NLM identifier: NCT01146561. Accessed 
April 15, 2012.
  54.  Allsop SA, Erstad DJ, Brook K, Bhai SF, Cohen JM, Dimitrakoff JD. The 
DABBEC Phenotyping System: towards a mechanistic understanding 
of CP/CPPS. Nat Rev Urol. 2011;8(2):107–113.
  55.  Mahal BA, Cohen JM, Allsop SA, et al. The role of phenotyping in 
chronic prostatitis/chronic pelvic pain syndrome. Curr Urol Rep. 2011; 
12(4):297–303.
  56.  Meares EM, Stamey TA. Bacteriologic localization patterns in bacterial 
prostatitis and urethritis. Invest Urol. 1968;5(5):492–518.
  57.  Stamey TA. Prostatitis. J R Soc Med. 1981;74(1):22–40.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
286
Kumar and MahalJournal of Pain Research
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/journal-of-pain-research-journal
The Journal of Pain Research is an international, peer-reviewed, open 
access, online journal that welcomes laboratory and clinical findings 
in the fields of pain research and the prevention and management 
of pain. Original research, reviews, symposium reports, hypoth-
esis formation and commentaries are all considered for publication.   
The manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Journal of Pain Research 2012:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
287
NGF – the TrkA to successful pain treatment